PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27045718-0	2016	[Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].	Docetaxel	63-72	DNA topoisomerase II alpha	Homo sapiens	19-24	
27045718-10	2016	CONCLUSIONS: Efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in TNBC patients can be predicted by detecting TOP2A, EGFR gene expression.	Docetaxel	25-34	DNA topoisomerase II alpha	Homo sapiens	126-131	
24007746-15	2013	INTERPRETATION: A short, four-cycle regimen of docetaxel and cyclophosphamide combined with trastuzumab could be an option for adjuvant treatment of women with lower risk HER2-amplified early breast cancer, irrespective of TOP2A status.	Docetaxel	47-56	DNA topoisomerase II alpha	Homo sapiens	223-228